Clinical Trial Update: A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating rivoceranib in combination with trifluridine/tipiracil for metastatic colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Rivoceranib (rivoceranib)
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: Elevar Therapeutics | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: TERMINATED